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Abstract
Loeys-Dietz syndrome (LDS) is an autosomal dominant arterial aneurysm disease belonging to the spectrum of transforming
growth factor b (TGFb)-associated vasculopathies. In its most typical form it is characterized by the presence of
hypertelorism, bifid uvula/cleft palate and aortic aneurysm and/or arterial tortuosity. LDS is caused by heterozygous loss of
function mutations in the genes encoding TGFb receptor 1 and 2 (TGFBR1 and 22), which lead to a paradoxical increase in
TGFb signaling. To address this apparent paradox and to gain more insight into the pathophysiology of aneurysmal disease,
we characterized a new Tgfbr1 mouse model carrying a p.Y378* nonsense mutation. Study of the natural history in this
model showed that homozygous mutant mice die during embryonic development due to defective vascularization.
Heterozygous mutant mice aged 6 and 12 months were morphologically and (immuno)histochemically indistinguishable
from wild-type mice. We show that the mutant allele is degraded by nonsense mediated mRNA decay, expected to result in
haploinsufficiency of the mutant allele. Since this haploinsufficiency model does not result in cardiovascular malformations,
it does not allow further study of the process of aneurysm formation. In addition to providing a comprehensive method for
cardiovascular phenotyping in mice, the results of this study confirm that haploinsuffciency is not the underlying genetic
mechanism in human LDS.
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Introduction
Although monogenetic disorders are rare, they offer a valuable
perspective for the study of common disease processes. The
Marfan syndrome (MFS), caused by mutations in the fibrillin-1
(FBN1) gene [1], has for example been successfully used as a model
to study the complex pathophysiology of aneurysm formation in
the thoracic aorta. Since FBN1 encodes the fibrillin-1 protein,
which is a major component of extracellular matrix microfibrils
[2], conventional knowledge held that most manifestations in
MFS, including aortic aneurysm formation, result from an
inherent structural weakness of connective tissues containing
abnormal microfibrils [3,4]. The study of the pathophysiology of
MFS in genetically modified mouse models recapitulating human
disease, has extended this knowledge by demonstrating that
fibrillin-1 also plays an important functional role in matrix
sequestration of transforming growth factor beta (TGFb), which
is crucial for regulating TGFb activation and signaling [5]. Studies
in different mouse models have shown that perturbation of TGFb
sequestration contributes to the pathogenesis of the disease [5–8].
Subsequent studies in various tissues from patients with MFS have
confirmed altered TGFb signaling in humans [9,10].
Based on these observations, inhibition of the TGFb signaling
pathway in mouse models by means of TGFb inhibiting agents,
such as the angiotensin II type I receptor blocker losartan, has
resulted in a significant reduction in aortic root growth and rescue
of aortic wall architecture [7]. Additional and very convincing
evidence for involvement of the TGFb pathway in aneurysmal
disease was provided by the identification of TGFBR1 and 22
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mutations in patients presenting a phenotype characterized by
aortic root aneurysm, arterial tortuosity and craniofacial malfor-
mations (including hypertelorism and bifid uvula/cleft palate),
called the Loeys-Dietz syndrome (LDS) [11]. Aortic aneurysms in
LDS tend to evolve more aggressively than in the MFS with rapid
growth and early dissection in most (but not all) cases [12].
Mutations in LDS most commonly reside within the intracellular
serine/threonine kinase domain of either the TGFBR1 (1/3 of
patients) or TGFBR2 (2/3 of patients) gene, encoding the TGFb
receptors [13]. The vast majority of all mutations identified in
TGFBR1 and TGFBR2 are missense mutations, however, other
mutation types, including nonsense (TGFBR1 and TGFBR2),
frameshift (TGFBR2) and splice site (TGFBR1 and TGFBR2)
mutations have also been identified [12,14] (Table S1). So far, no
significant genotype-phenotype correlations have been delineated
when comparing both genes or different types of mutations.
Previous co-transfection experiments suggested a mild dominant-
negative effect for TGFBR1 and 22 missense mutations resulting
in loss of signaling potential of the receptors [15,16]. No detailed
studies have been performed to investigate the effect of other
TGFb receptor gene mutation types. In aortic tissue from patients
with either TGFBR1 or 22 mutations, unexpected upregulation of
TGFb signaling was demonstrated by an increased expression of
the downstream effector, i.e. connective tissue growth factor
(CTGF), and accumulation of nuclear pSmad2 [11]. This
phenomenon has been referred to as the TGFb paradox. In
order to study this apparent paradox, we generated a new Tgfbr1
mouse model aiming to mimic human LDS.
Several Tgfbr1 and Tgfbr2 mouse models have already been
developed and studied. These models showed that both receptors
are required for correct TGFb signaling since homozygous Tgfbr1
and 22 knock-out mice and conditional Tgfbr1 and 22 knock-out
models for vascular smooth muscle cells and endothelial cells die
prematurely due to abnormal vasculo- and angiogenesis [17–20].
Interestingly, conditional deletion of Tgfbr1 or 22 in neural crest
cells results in immediate postnatal lethality due to either
cardiovascular or pharyngeal defects, including persistent truncus
arteriosus, interrupted aortic arch and inappropriate remodeling
of pharyngeal arch arteries [21,22]. Although these early models
for either of the TGFb receptors clearly indicate that TGFb is
involved in various steps of cardiovascular development, they were
not suitable for the study of the molecular and pathogenetic
mechanism of LDS. First, all homozygous mutant mice presenting
cardiovascular features die prematurely, either during embryonic
development or in the early postnatal period. Second, heterozy-
gous knock-out mice do not develop any phenotypic abnormality.
These previous reports, however, all focused on the embryonic
and early postnatal phase and no in depth analysis of the
cardiovascular system was performed in adult heterozygous mice.
This leaves the possibility that these heterozygous knock-out mice
develop a cardiovascular phenotype later in life. For example, it
was reported previously that heterozygous Tgfb2 knock-out mice
do not show a phenotype in contrast to the homozygous mutant
mice that show late embryonic lethality secondary to congenital
heart disease [23]. Following the identification of loss of function
mutations in the Tgfb2 gene in humans with thoracic aortic
aneurysm, however, the mouse model was revisited and Lindsay
and colleagues showed that the haploinsufficient Tgfb2 mice
(Tgfb2+/2) showed significant dilatation of the aortic annulus and
root at the age of 8 months [24]. This observation further warrants
a more in depth cardiovascular evaluation of Tgfbr mouse models.
Theoretically, mice are good models for the study of the TGFb
receptor type 1, since the sequence homology between humans
and mice is very high (91.12% genomic level, 97.19% protein
level).
In a collaborative research effort between our group and the
group of H. Dietz (Baltimore) several Tgfbr1 and22mouse models
with either a missense or nonsense mutation in one of the receptor
genes were investigated. In addition to the search for a suitable
model for the study of aneurysm formation in LDS and the TGFb
paradox, this study was also set up to optimize cardiovascular
phenotyping in mouse models.
Methods
Ethics statement
For all procedures the Principles of Laboratory Animal Care
(NIH publication 86–23, revised 1985) were followed. All
procedures were approved by the Ghent University Hospital
ethical committee for laboratory animal testing (Permit Number:
ECD07/20). All in vivo non-invasive imaging was performed
under anesthesia, and all efforts were made to minimize
suffering.
Mice
Mice were generated by Ingenium according to the procedure
described by Augustin et al [25]. Upon screening of a library
containing mutant mouse sperm that were generated by N-ethyl-
N-nitrosurea (ENU) mutagenesis in healthy C3HeB/FeJ males, a
nonsense mutation was identified in exon 7 of the Tgfbr1 gene
(p.Y378*). Subsequently, these mice were backcrossed to a
C57BL/6 background.
Genotyping mice
Mice were toe-clipped and tail-clipped between postnatal day 8
and 10. The DNA fragment containing the p.Y378* mutation was
amplified from crude tail lysate using the KAPA 2GTM Robust
Hotstart kit (Kapabiosystems). Subsequently, PCR products were
sequenced using the Sanger sequencing technique on an ABI
3730XL Sequencer (Life Sciences).
Determination of the lethal phase of homozygous
mutant embryos
Pregnant female mice were euthanized by means of cervical
dislocation at day 8.5–12.5 post coitus (dpc). The uteruses of the
mice were dissected and embryos were collected. Embryos were
either snap-frozen in liquid nitrogen for RNA isolation or fixated
in Bouin solution (Sigma-Aldrich) for 2 hours and then incubated
in 70% ethanol and embedded in paraffin for histological
examination.
In vivo imaging
Echocardiography. Prior to the imaging studies, mice were
anesthetized (1.0% to 1.5% isoflurane mixed with 0.5 L/min
100% O2) and coat hairs were removed with hair removal cream.
Anesthetized mice were placed in dorsal recumbency on a warmed
pad, keeping the body temperature around 37uC. Throughout the
examination the heart rate, respiration rate and body temperature
were monitored. Ultrasound data of the thoracic aorta and left
ventricle were obtained in 4 wild-type and 4 heterozygous mutant
mice at 6 months and 9 wild-type and 9 heterozygous mice at
12 months of age with an ultrasound apparatus (Vevo 2100,
VisualSonics) equipped with a high-frequency linear array
transducer (MS 550D, frequency 22–55 MHz). The diameter of
the aorta was measured from the parasternal, and suprasternal
windows at the level of the annulus, sinus of Valsalva, ascending
Tgfbr1 Mouse Model
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aorta, aortic arch, and descending thoracic aorta (Figure S1).
Diameters were measured in diastole from inner to inner edge.
Left ventricular dimensions were obtained in M-mode from
parasternal short axis view, according to standard methods.
Fractional shortening was used as parameter for left ventricular
function (FS = (LVEDD-LVESD/LVEDD)*100; with LVEDD
= left ventricular end diastolic diameter, LVESD = left
ventricular end systolic diameter). Standard LV diastolic function
parameters were obtained with the combination of transmitral
pulsed Doppler and mitral annular TDI. Transmitral Doppler
signals were obtained by placing the sample volume of the pulsed
Doppler between the tips of the mitral leaflets in the apical four-
chamber (4C) view. Early (E) and late (A) transmitral flow
velocities, the ratio of early to late peak velocities (E/A) and
deceleration time of E velocity (DT) were obtained. TDI derived
indices, early (Em) and late (Am) mitral annulus velocities were
recorded using pulsed wave TDI mode by positioning the Doppler
cursor at the septal atrioventricular margins of the LV in the apical
four-chamber images.
Micro-CT. Four animals of each genotype group and each
time point were anesthetized with 1.5% isoflurane mixed with
0.5 L/min 100% O2 and, once anesthetized, Aurovist (Nanop-
robes) at a dose of 150 microliter/25 gram body weight was
injected intravenously in the lateral tail vein. Immediately after
injection, when the contrast was maximal, the animals were
scanned in supine position in a FLEX Triumph-II CT scanner
(Gamma Medica-Ideas). The acquisition parameters were the
following: 50 mm focal spot, 262 detector binning, 1024
projections over 360u, 3 times magnification, and 70 kVp tube
voltage. The data was reconstructed with proprietary software
(Cobra EXXIM) using a Feldkamp-type algorithm with Parker’s
weighing function in a 51265126512 matrix with a 75 mm voxel
size. Reconstructed images were converted into DICOM standard
format, and imported into the 3D segmentation software package
Mimics (Materialise). The aorta was semi-automatically segmented
to select the (contrast-enhanced) lumen, requiring manual
intervention to separate aortic and venous segments. The resulting
mask was then wrapped and smoothed while care was being taken
not to cause any shrinkage. This resulted in a 3-D reconstruction
of the thoracic aorta, including the aortic arch and its three major
branches (brachiocephalic artery, left common carotid artery, and
left subclavian artery). Due to movement artifacts caused by the
proximity of the heart, no reliable reconstruction could be made of
the aortic annulus and sinus. A centerline was calculated in
Mimics, and at the ascending aorta, aortic arch and descending
aorta the local cross-sectional area was measured orthogonal to the
centerline.
PET. PET imaging was conducted using the same FLEX
Triumph-II (Gamma Medica-Ideas) system as used with micro-
CT imaging. This system consists of a micro-PET module
(LabPET8) with 262610 mm3 LYSO/LGSO scintillators in an
8-pixel, quad-APD detector module arrangement. This allows for
a 1.5 mm spatial resolution in rodents at a sensitivity of 4%,
thereby covering a field-of-view of 10 cm transaxially and 8 cm
axially. Both the CT and PET modules are attached to the same
system, leading to perfect co-registration of both modalities.
Six mice (4 heterozygous, 2 wild-type) were fasted overnight,
after which they received an intravenous injection of 19.8961.44
MBq of [18F]-fluorodeoxyglucose (FDG). After 40 minutes of
uptake without anaesthesia, the animals were anesthetized with
1.5% isoflurane mixed with 0.5 L/min 100% O2 and scanned for
30 minutes in two bed positions. The PET data were iteratively
reconstructed by 60 iterations of the 2D MLEM algorithm with a
span of 31 to obtain a 92692695 matrix of 0.560.561.175 mm
voxels. The PET data was evaluated in VIVID (GMI) by
calculating the percentage of injected dose (%ID) inside the aorta.
The relevant aorta volume was determined from the aorta
segmentation obtained from the contrast-enhanced micro-CT
scan.
Ex vivo fluorescence reflectance imaging
Increased activity of MMPs (matrix metalloproteinases) can be
assessed using long-circulating protease-activatable near infrared
fluorescent probes. These autoquenched fluorescence probes
convert from a non-fluorescent to a fluorescent state by
proteolytic activation and can be used as a sensitive readout
that reflects subtle changes in protease activity in the extracel-
lular matrix in pre-aneurysmal lesions [26]. The proteolytic
activity comes from MMPs that can cleave an MMP-specific
recognition sequence between the carrier and the fluorochromes
of these probes [27]. Four mice (2 heterozygous Tgfbr1 mice, 2
wild-type mice) were injected via tail vein injection with 5nmol
MMPsense 680 (Perkin Elmer). Twenty-four hours after injection
the animals were sacrificed and aortas were harvested for ex vivo
examination using the Odyssey imaging system. Near infrared
images were obtained at the 700 nm channels and analysed on
relative fluorescence.
Vascular corrosion casting
The vascular corrosion casting procedure was performed as
previously described [28]. In short, mice (8 wild-type and 8
heterozygous mutant mice of both 6 and 12 months old) were
starved 24 hours before sacrificing them by means of CO2
asphyxiation. The abdominal aorta was dissected and 3 ml of
Batson polymer (Polysciences) was injected through a 26 gauche
catheter. After polymerization, mouse bodies were macerated
overnight in 25% potassium hydroxide and rinsed. The casts of the
arterial blood vessels were evaluated using a dissecting microscope
with 5-megapixel camera (Leica).
Statistical analyses
Results are presented as mean (standard deviation (SD) in
parentheses). Data were analyzed with the unpaired sample t-test
for normal-distributed continuous variables; non-normal distrib-
uted values were compared using the Mann-Whitney-U test. x2
test was used to compare categorical variables. If not all cells had
an expected count of 5 or more, Fisher’s Exact test was applied. A
p-value of ,0.05 was used to define statistical significance (two-
sided). SPSS version 20.0 was used for the statistical analysis (SPSS
Inc, Chicago, IL, USA).
Cell cultures
In order to obtain aortic smooth muscle cells, 6 wild-type and 6
heterozygous mutant mice of both 6 and 12 months old, were
euthanized with CO2 and the thoracic aorta was dissected. The
following steps were previously described by Ray and colleagues
[29].
Aortic smooth muscle cells were grown in SmBM smooth
muscle cell basal medium supplemented with 5% fetal bovine
serum, antibiotics and antimycotics, and growth supplements
(0,1% hEGF, 0,1% insulin, 0,2% hFGF-B and 0,1% GA-1000)
(Lonza) at 37uC and 5% CO2. Cells were harvested when a
monolayer was formed and RNA was isolated.
cDNA analysis
RNA was isolated from cultured aortic smooth muscle cells
from adult mice on the one hand and whole snap-frozen embryos
Tgfbr1 Mouse Model
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on the other hand using the RNeasy Mini kit (Qiagen).
Subsequently, cDNA was synthesized using the Superscript II
reverse transcriptase kit with random hexamer primers (Invitro-
gen). cDNA was amplified using primers spanning the entire exon
7 of the Tgfbr1 gene. The PCR product was analyzed on a Labchip
analyzer (Calliper) and subsequently Sanger sequenced on an
3730XL Sequencer (Life Sciences).
Quantitative real-time PCR
RT-qPCR was carried out on cDNA samples using the Roche
56mastermix and resolight dye (Roche) on the LC480 machine
(Roche). All reactions were carried out in duplicate and
normalized to the geometric mean of two reference mouse specific
repeat sequences.
Western blot analysis
Proteins were isolated from snap-frozen thoracic aortic tissue
of 2 heterozygous and 2 wild-type mice for each time point. The
lysis buffer (RIPA, Sigma-Aldrich) was complemented with
protease (Roche) and phosphatase inhibitors (Sigma-Aldrich).
Protein samples were reduced by boiling and adding dithiothre-
itol (DTT) and loaded on a NuPage 4–12% Bis-Tris gel
(Invitrogen) together with a 56 non reducing lane marker
sample buffer (Thermo Scientific). Following SDS-PAGE, the
proteins were transferred onto a nitrocellulose membrane using
the iBlot dry blotting system (Invitrogen). The membranes were
blocked in 2% ECL advantage blocking buffer (GE Healthcare)
and incubated overnight at 4uC with primary antibody directed
against phosphorylated p44/42 MAPK (ERK1/2 XPTM rabbit
mAb (Cell Signaling Technologies) (1/1000)). Subsequently, the
membranes were incubated with secondary anti-rabbit IgG
HRP-linked antibody (Cell Signaling Technologies) (1/5000).
Membranes were developed with the SuperSignal West Dura
chemiluminescent substrate (Pierce). Membranes were then
stripped and re-blocked, in order to incubate with a primary
antibody directed against the non-phosphorylated form of p44/
42 MAPK (ERK1/2) (Cell Signaling Technologies). Next, the
membranes were again incubated with the secondary antibody
and developed. Quantification of the signal was performed using
Image J software (NIH).
Histological, immunohistochemical and
immunofluorescent analyses
Paraffin-embedded thoracic aortic tissue samples from 4
heterozygous mutant and 4 wild-type mice from each time point
were made. From these formalin (for embryos Bouin)-fixed,
paraffin-embedded specimens, 5 mm-thick sections were made.
Hematoxylin-eosin and Verhoeff-Von Giesson stainings were
performed according to standard protocols. For immunohisto-
chemistry, epitopes were unmasked using 1mM EDTA pH 8
buffer (not for actin) and auto-peroxidase activity was inhibited
by incubation in 3% H2O2. Sections were blocked with 5%
bovine serum albumin (Sigma-Aldrich). Antibodies directed
against CTGF (Abcam), pSmad2 (Ser465/467) (Cell Signaling
Technologies) and smooth muscle a-actin (Sigma-Aldrich) were
used. Subsequently, sections were incubated with a secondary
antibody, either biotinylated goat anti-rabbit IgG (pSmad2 and
CTGF) (Vectastain) or Cy3-labeled donkey anti-goat (smooth
muscle a-actin) (GE Healthcare). When the biotinylated second-
ary antibody was used, sections were incubated subsequently with
ABC (Avidin: Biotinylated enzyme Complex) reagent (Vectastain)
and DAB (3,39-Diaminobenzidine) peroxidase (Vectastain). Sec-
tions were dehydrated in xylene and mounted with Entellan
(Sigma Aldrich). When the Cy3-labeled antibody was used,
sections were immediately mounted with aqueous mounting
medium (Vectastain).
Results
Development of the Tgfbr1 mouse model
A chemical ENU mutagenesis process was used to develop
Tgfbr1 mutant mouse sperm (Ingenium). Four out of six induced
mutations included an intronic mutation, two silent mutations
and one missense mutation predicted to have a low pathological
risk according to the small physicochemical difference between
the substituted and substituting residues. One nonsense mutation
and one missense mutation were of potential pathogenic interest.
In this study, the mouse sperm with nonsense mutation in exon 7
of the Tgfbr1 gene (p.Y378*) was used for in vitro fertilization,
creating a mouse line with a germ line mutation in the Tgfbr1
gene.
Natural history of the Tgfbr1 mouse model
Upon genotyping of the offspring of two heterozygous p.Y378*
mice 8 days after birth, no homozygous p.Y378* mice were
identified, which suggested that these mice die during embryonic
development. In contrast, heterozygous mutant mice developed
normally, were fertile and had a normal lifespan, similar to their
wild-type littermates.
To determine the lethal phase of the homozygous mutant mice,
pregnant females were sacrificed at 8.5 through 12.5 days post
coitus (dpc). This time frame was selected based on the lethal
phase of homozygous Tgfbr1 and 22 knock-out mice [19,20]. At
8.5 dpc the homozygous mutant mice were indistinguishable from
their heterozygous mutant and wild-type littermates. By day 9.5,
homozygous mutant mice showed developmental delay, enlarged
pericardium, and defective vascularization of the yolk sac. By
day 11.5 all homozygous mutant embryos died. Complete
resorption occurred by embryonic day 12.5 (Figure 1).
The cardiovascular system
We studied the cardiovascular system of heterozygous p.Y378*
mice and their sex-matched wild-type littermates at 1, 3, 6 and
12 months of age. Experiments were initiated in the groups aged 6
and 12 months. Several invasive and non-invasive imaging
techniques were applied for detailed investigation of the cardio-
vascular system with special attention paid to the aorta. Initial
studies with echocardiography of the 6-month-old mice showed no
significant differences in aortic diameter, valvular function or left
ventricular dimension and function between heterozygous mutant
and wild-type mice, as was also the case at 12 months of age
(Table S2). Micro-CT was performed at both time points and
images were reconstructed and segmented to create a 3
dimensional (3-D) model of the aorta. No differences in aortic
diameter were noted between heterozygous p.Y378* and wild-type
mice, neither at 6 nor at 12 months of age (Figure 2). Further-
more, no tortuosity of the aorta or branching vessels was observed
in the mutant mice. Perturbation of normal elastin laminar
structure may arise from induction of TGFb regulated matrix
metalloproteinases (MMP), a family of endopeptidases responsible
for the degradation of the extracellular matrix in aortic aneurysms
[30]. This increased activity of MMPs can be assessed using ex vivo
fluorescence reflectance imaging. We compared aortas from Tgfbr1
mutant mice to wild-type littermate controls and observed no
difference in the intensity of the fluorescent signal, excluding
minor molecular changes at the level of MMPs in the aortas of
Tgfbr1 muatnt mice (Figure S2). PET-CT was performed to
Tgfbr1 Mouse Model
PLOS ONE | www.plosone.org 4 February 2014 | Volume 9 | Issue 2 | e89749
investigate the presence of an inflammatory reaction that may
precede aneurysm formation. On the PET images no inflamma-
tory activity was seen that co-localized with the aorta (Figure 3).
Also vascular corrosion casting, a technique allowing us to
construct a plastic replica of the arterial system of the mice, did
not demonstrate any aortic aneurysms or tortuosity of the aorta
and/or its major branches, including the carotid arteries, both at 6
and 12 months of age (Figure 2, Table S3). Due to the complete
absence of a cardiovascular phenotype in these older mice, it is
unlikely that younger mice present any features. Therefore,
imaging and further functional analyses of the 1- and 3-month-
old mice were no longer scheduled.
Nonsense mediated mRNA decay
In a next step, the reason for the absence of a disease
phenotype in the Tgfbr1 mouse model was investigated. The
nonsense mutation p.Y378* is located at the beginning (second
amino acid residue) of exon 7, the last but two coding exon of
the Tgfbr1 gene. Hence, according to the rules of nonsense
mediated mRNA decay (NMD), the mutant mRNA is expected
Figure 1. Morphology of wild-type, heterozygous and homozygous mutant mouse embryos at different time points. At 8.5 dpc
mutant embryos are indistinguishable from their wild-type littermates. From 9.5 dpc onwards homozygous mutants show an abnormal development
characterized by growth retardation and enlarged pericard (white arrow, right panel). By embryonic day 11.5 most of the embryos died and complete
resorption is a fact by day 12.5. Heterozygous mutant Tgfbr1 embryos and wild-type embryos develop normally.
doi:10.1371/journal.pone.0089749.g001
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to be degraded in this mouse model. In order to detect NMD we
first attempted to amplify cDNA from homozygous mutant
embryos. When NMD takes place, no mutant cDNA is expected
to be present in the homozygous mice, which could be confirmed
here (data not shown). Subsequent sequencing of the PCR
products revealed the (near) absence of the mutant allele carrying
the C to A substitution in the heterozygous mice (Figure 4A). In
a second step, the sequencing results were validated using qPCR.
These experiments confirmed the 650% reduction in expression
of Tgfbr1 mRNA in heterozygous embryos and the almost
complete absence of Tgfbr1 mRNA in homozygous mutant
embryos (p,0.05) (Figure 4B).
Aortic wall and TGFb signaling
The architecture of the aortic wall in heterozygous p.Y378*
mice was similar to that of their wild-type littermates. Fragmen-
tation of elastic fibers, one of the main characteristics of aortic
media degeneration, could not be detected upon Verhoeff-Von
Giesson elastin staining (Figure 5 a–d). Also, smooth muscle a-
actin staining showed no smooth muscle cell loss in heterozygous
Tgfbr1 mutant mice (Figure 5 m–p).
In order to investigate upregulation of the canonical TGFb
signaling pathway as observed in human LDS, we performed
immunohistochemical staining of pSmad2 and CTGF on aortic
tissue of 6- and 12-month-old mice (Figure 5 e–l). No significant
differences in pSmad2 and CTGF staining were observed between
heterozygous mutant mice and wild-type mice at both time points.
Despite several attempts, our immunohistochemical data could not
be verified by western blot. Following recent findings of increased
non-canonical TGFb signaling in an MFS mouse model, we
investigated pERK1/2 levels by western blot (Figure 6). No major
differences in the amount of active ERK1/2 (pERK1/2) were
observed between wild-type and heterozygous mutant mice at
both time points (p.0,05).
Discussion
The principal aim of this study was to develop a mouse model
for LDS allowing investigation of the role of TGFb signaling in
aortic aneurysm formation. We also aimed to develop a robust
protocol for cardiovascular phenotyping in mice, combining
functional, anatomical and molecular imaging with in depth
histological characterization of the aortic wall. The Tgfbr1
nonsense mouse model was selected based on the available data
at that time, including observations that nonsense mutations in the
TGFBR2 gene result in LDS in humans, and conditional (neural
crest) Tgfbr1 and 22 knock-out mice display important cardio-
vascular abnormalities [21,22]. During the course of this study,
Figure 2. 3-D reconstruction micro-CT images and vascular
corrosion casts of wild-type and heterozygous Tgfbr1 mice. No
aortic aneurysm nor aortic/arterial tortuosity was observed by micro-CT
(upper panel) or vascular corrosion casting (VCC – lower panel) in
heterozygous mice (right) compared to wild-type controls (left)
(6 months old).
doi:10.1371/journal.pone.0089749.g002
Figure 3. PET imaging of wild-type and heterozygous Tgfbr1 mice (6 months old). No FDG-PET activity (green-yellow) is seen in
heterozygous mice that co-localizes with the thoracic aorta. Top row: Micro-CT reconstruction with thoracic aorta segmentation in red. Middle row:
PET. Bottom row: PET/CT.
doi:10.1371/journal.pone.0089749.g003
Tgfbr1 Mouse Model
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TGFBR1 nonsense mutations have also been identified in human
LDS, further reinforcing the choice for this model.
In our new Tgfbr1 mouse model, the phenotype was limited to
early embryonic lethality of homozygous mutant mice. Heterozy-
gous mice did not display a cardiovascular disease phenotype,
which is in line with previous findings in both Tgfbr1 and Tgfbr2
knock-out mouse models [19,20]. The lack of vascular, anatomical
or immunohistological anomalies in the heterozygous mutant mice
is in contrast with the manifestations encountered in humans
harbouring mutations in the TGFb receptor genes. Both missense
and premature termination codon mutations in these genes give
rise to LDS in humans ([14,31], personal communication C.
Boileau and E. Arbustini). The effect of the TGFBR1 and 22
nonsense mutations has not been described yet. However, based
on the theoretical rules of the nonsense mediated mRNA decay
(NMD) process one could expect the reported TGFBR2 nonsense
mutations to escape this process, because these mutations are all
located in the final coding exon or within less than 50–55
nucleotides before the final exon-exon junction and as such the
exon junction complexes will be displaced after initial translation
and these complexes will not serve as assembly platforms for NMD
factors. Possibly, these truncating mutations act in a moderate
dominant-negative manner similar to what was observed for
missense mutations [16]. In contrast, the nonsense mutations
identified in TGFBR1 are both located before this theoretical
‘boundary’ and as such are predicted to result in NMD. Whether
this is indeed the case for both the TGFBR1 and 22 nonsense
mutations is not known so far. The 2 TGFBR1 splice site mutations
identified by the group of C. Boileau affect 39 and 59 splicing of
intron 4 (personal communication C. Boileau). Unfortunately, no
biological material is available to assess whether these mutations
lead to NMD. Although knowledge of the mutation spectrum in
LDS increased over the years, the exact underlying disease
mechanism remains elusive. However, the existence of a
haploinsufficient disease mechanism seems unlikely, since hetero-
zygous Tgfbr1 and 22 knock-out mice develop normally, and have
a normal life span [19,20]. Human data in support for the absence
of a haploinsufficiency model include a study published by Redon
and colleagues, who identified a heterozygous de novo microdele-
tion (9q22.32-q22.33), encompassing the TGFBR1 gene, in two
unrelated patients who present overgrowth and psychomotor delay
but do not show any of the typical LDS features [32]. Another
argument against a haploinsufficiency disease mechanism is the
demonstration of a mild dominant-negative effect of TGFBR1 and
TGFBR2 missense mutations in human HEK293 cell cultures
[15,16]. For instance, co-transfection of mutant TGFBR1 reporter
constructs with an eGFP (enhanced green fluorescent protein)-
tagged Smad2 construct showed that missense mutations in the
serine/threonine kinase domain of the type I receptor either
affected the activation of TGFb receptor type I by the type II
Figure 4. Nonsense mediated mRNA decay of the mutant Tgfbr1 allele. (A) Sequencing of the amplified cDNA confirms the absence of the
mutant allele in heterozygous (ht) and homozygous mutant mice (hm) compared to wild-type mice (wt). (B) qPCR indicates (near) absence of Tgfbr1
mRNA in homozygous mutant mice (black bar), and an average of 50% reduction in heterozygous mutant mice (light grey bar) compared to wild-
type mice (dark grey bar) (** indicates that p,0.05). Some natural biological variation is seen within the groups (data not shown). Y-axis indicates
relative expression of Tgfbr1 mRNA. gDNA: genomic DNA; cDNA: complementary DNA.
doi:10.1371/journal.pone.0089749.g004
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receptor, or inhibited the phosphorylation of receptor-Smads [15].
Co-transfection of equal amounts of wild-type and mutant
TGFBR1 revealed a modest downregulation of TGFb signaling,
providing evidence for, at least a moderate, dominant-negative
effect of the mutant receptor [15]. Here, we show that our model
does not recapitulate the LDS phenotype and therefore our study
Figure 5. (Immuno)histological and immunofluorescent staining of murine aortic tissue. Upper panel: Verhoeff-Von Gieson (VVG) staining
shows intact elastic fibers in both wild-type (wt) (a,c) and heterozygous (ht) Tgfbr1 mice (b,d) of 6 and 12 months of age. Middle panels: no
upregulation of the TGFb signaling pathway, characterized by increased cytoplasmatic CTGF staining (i–l) and accumulation of nuclear pSmad2
staining (e–h), is seen in heterozygous 6 months (f and j) and 12 months (h and l) old mice compared to wild-type mice (e, i, g and k). Lower panel:
aortic tissue of heterozygous Tgfbr1 mice (n and p) is not characterized by smooth muscle cell loss or focal hyperproliferation of smooth muscle cells
compared to wild-type mice (m and o) (red staining). SM-actin: smooth muscle a-actin.
doi:10.1371/journal.pone.0089749.g005
Figure 6. Western blot of non-canonical TGFb signaling pathway. (A) Western blot analysis of pERK1/2 (44 kDa band pERK1 and 42 kDa band
pERK2) in wild-type (wt) and heterozygous mutant (ht) mice of 6 and 12 months old shows no major increase or decrease of the active
(phosphorylated) form of ERK1/2 in these groups compared to total ERK1/2 and b-tubulin. (B) The graphs show normalization of pERK1/2 to total
ERK1/2 and b-tubulin protein expression. Y-axis indicates relative protein expression. NS: not significant.
doi:10.1371/journal.pone.0089749.g006
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further confirms that a TGFBR1 haploinsufficient disease mech-
anism is very unlikely in LDS, as the development of the
cardiovascular system remains unaffected notwithstanding the
50% reduction in Tgfbr1 mRNA in heterozygous animals.
Nonetheless, haploinsufficiency of other TGFb signaling compo-
nents, such as the SMAD3 effector and the TGFb2 ligand, which
also leads to pathologically increased TGFb signaling has
previously been suggested as the disease mechanism causing
thoracic aortic aneurysms and various associated features
[24,33,34].
Recently, TGFBR1 nonsense mutations have been identified in
patients with multiple self-healing squamous epithelioma (MSSE,
MIM 132800) [37]. As opposed to LDS, in which predominantly
missense mutations in the kinase domain of the receptor lead to a
cardiovascular, neurocognitive and craniofacial-skeletal pheno-
type, only truncating mutations are identified in the kinase domain
of the receptor in MSSE patients, together with truncating and
missense mutations in the ligand-binding extracellular domain of
the type I receptor. As such, the differences in the spectrum and
location of mutation types determine the phenotype. A macro-
scopic evaluation of the skin of fifteen 12-month-old heterozygous
Tgfbr1 mice did not reveal any scars as observed in human MSSE
patients after spontaneous regression of the skin tumors. More
thorough assessment of the skin of this model, for example by
challenging it with known cancerogens, is needed to evaluate the
skin phenotype.
Other possible explanations for the absence of a disease
phenotype in these mice should also be considered. First, the
decrease in Tgfbr1 signaling that ought to be caused by
haploinsufficiency could be compensated for by other receptors
of the TGFb superfamily. For instance, it was shown by Carvalho
and co-workers that the ALK4 receptor is able to phosphorylate
SMAD2 in a conditional Tgfbr12/2 (also known as Alk5) knock-out
mouse model, compensating for the reduction in Tgfbr1 signaling
[17]. Second, reduced penetrance of the phenotype might relate to
the genetic background (black 6) of the mouse strain used in this
study. This hypothesis is supported by the study of Tang and
colleagues, who identified three unlinked genetic modifiers which
may regulate TGFb activation as shown by the survival-to-birth
rate in different strains in which Tgfb1 was deleted [35,36].
Since the TGFb signaling pathway is thought to play a crucial
role in the pathophysiology of thoracic aortic aneurysms and the
therapeutic implications hereof, it is of utmost importance to
unravel the precise role of the TGFb signaling pathway in aortic
disease and understand the seemingly paradoxical upregulation of
this pathway in LDS patients. Mouse models bearing missense
mutations previously identified in human LDS patients could
possibly model the disease and be instrumental in identifying it’s
pathogenetic mechanism.
In conclusion, the haploinsufficient Tgfbr1 mouse model created
in this study does not recapitulate the human LDS phenotype.
Consequently, we were not able to elucidate the TGFb paradox
that has been previously proposed to occur in LDS. In view of the
similarity to mutations identified in MSSE, this model might be
valuable for further studies of the pathogenesis of this phenotype.
Furthermore, with the combination of detailed phenotyping
techniques, we provide a useful protocol for the characterization
of cardiovascular features in mice. Our protocol may be of
practical use for other researchers in the field.
Supporting Information
Figure S1 Sites of measurement of the thoracic aorta
diameters on echocardiographic evaluation. (1) aortic
annulus, (2) sinus aortae, (3) sinotubular junction, (4) ascending
aorta, (5) aortic arch, and (6) descending aorta.
(TIF)
Figure S2 Fluorescence imaging of MMP activity in
aortas from wild-type and heterozygous Tgfbr1 mice.
Near infrared fluorescence images showing the fluorescence of
MMPsense 680 ex vivo in the thoracic aorta at 24 hours post-
injection. Shown are an uninjected control aorta, 2 wild-type and
2 heterozygous Tgfbr1 aortas.
(TIF)
Table S1 Overview of reported and unpublished
TGFBR1 and TGFBR2 premature termination codon
mutations identified in LDS patients. CMGG: Center for
Medical Genetics Ghent.
(XLSX)
Table S2 Echocardiographic data of wild-type and
mutant Tgfbr1 mice at 6 and 12 months of age. WT:
wild-type; Stdev: standard deviation; LVEDD: left ventricular end
diastolic diameter; LVESD: left ventricular end systolic diameter.
FS: fractional shortening; E: early transmitral flow velocity; A: late
transmitral flow velocity; DT: deceleration time of E velocity, E/
A: ratio of early (E) to late (A) peak velocities; Em: early mitral
annulus velocity; E/E’: relationship between maximal values of
passive mitral inflow.
(XLSX)
Table S3 Aortic diameters measured from vascular
corrosion casts of wild-type and mutant Tgfbr1mice at 6
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